Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Willingness to follow trial procedures for the duration of the trial.
You may not be if
Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
Previous or planned surgical, endoscopic or device-based treatment for obesity.
History of malignancy.
Type 1/Type 2 diabetes mellitus (DM).
Family or personal history of medullary thyroid cancer.
Previous participation in a Maridebart Cafraglutide trial.
Clareo Health | Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
